Novo Nordisk and Eli Lilly took their GLP-1 pill battle to the preeminent obesity meeting this weekend as they prepare for the next sea change in how patients receive their drugs.
CNBC’s Angelica Peebles explains.
Thursday, June 11
Add A Comment